Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA’s 2002 Regulatory Agenda, In Brief

Executive Summary

IRB registration: FDA to propose rule requiring institutional review boards to register with the agency. Registration information would include name of institution operating the IRB, detailed contact information for "the senior officer of the institution and IRB chair or contact, the range of active protocols...involving FDA-regulated products reviewed in previous calendar year, and a description of the types of...products reviewed." The rule is intended to "make it easier for FDA to inspect IRBs and to convey information to IRBs," HHS' Unified Agenda for 2002 explains. FDA is also endorsing a voluntary IRB accreditation system...

You may also be interested in...



Gregg Clinical Research Bill To Address Conflict Of Interest Without Caps

A bill to reform the human subject protection system under development by Sen. Judd Gregg (R-N.H.) will attempt to find a way to address potential conflict of interests without using caps on compensation

Gregg Clinical Research Bill To Address Conflict Of Interest Without Caps

A bill to reform the human subject protection system under development by Sen. Judd Gregg (R-N.H.) will attempt to find a way to address potential conflict of interests without using caps on compensation

HHS Human Research Protections Office Gains FDA Science Advisor Schwetz

HHS Office for Human Research Protections Acting Director Bernard Schwetz, PhD, will facilitate coordination between HHS and FDA on human subject protection activities

Related Content

UsernamePublicRestriction

Register

PS039094

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel